Cyprium Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.cypriumtx.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Long Term Follow-up on Menkes Disease Patients
- Conditions
- Menkes Disease
- Interventions
- Drug: Long Term Follow-Up
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cyprium Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04337684
- Locations
- 🇺🇸
Cyprium Study Team, New York, New York, United States
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Phase 3
Completed
- Conditions
- Unexplained Copper DeficiencyMenkes DiseaseOccipital Horn Syndrome
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Cyprium Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT00811785
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
News
No news found